ProQR Therapeutics NV PRQR shares are trading higher by more than 52% after the company reported results Wednesday from its trial of QR-421a in Usher Syndrome, though the stock did not surge initially.
ProQR is a biopharmaceutical company that develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Trending Investment Opportunities
Cellect Biotechnology Ltd - ADR APOP shares are trading higher after the company and Quoin Pharmaceuticals announced a strategic merger.
Cellect is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.